I would like to highlight all the help we have received and still receive from national and international researchers from academia, hospitals and life sciences industry so that we can fulfil the ambition to strengthen the research training available to junior researchers within the field of diabetes and serve as a national hub within diabetes.
 
Two weeks ago, we managed within only 36 hours with priceless help from 18 speakers to convert the traditional PhD course in basal metabolism from a physical presence course into an online course.
 
These weeks, during webinars and with help from Novo Nordisk, Zealand Pharma, Sanofi Aventis, RSP systems, Nordic Bioscience and Follicum, we have the pleasure of providing junior researchers with information on how it is to work as a scientist in the life sciences industry.
 
In addition, the biotech company Gubra has shared and will share their knowledge on new technology on measuring beta-cell volume and how to improve the translatability of rodent models of diabetic kidney disease.
 
We have also held a number of webinars with DDA Visiting Professors. Four more webinars will be held in the nearest future on the following topics: The COVID-19 pandemic in relation to gestational diabetes; The euglycaemic hyperinsulinaemic clamp for muscle insulin sensitivity; Sex, Drugs and Exercise; and Islet cell sub-types in health and type 2 diabetes.
 
All webinars are recorded and will be available soon at the DDA website.
 
The next newsletter, which we will release on 10 December, will include information about who have received the DDA PhD scholarships, postdoc fellowships and visiting professorships (with application deadline in August 2020). 

Until then, I wish you all the best.

Tore Christiansen
Managing Director

Read the full newsletter